NovaBridge Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	-	0.63	-1.55	13.85
Revenue Growth (YoY)	-	-	-	-	-94.14%
Cost of Revenue	-	-	-	-	46.43
Gross Profit	-	-	0.63	-1.55	-32.58
Selling, General & Admin	31.36	29.66	28.16	28.98	141.59
Research & Development	62.91	21.77	21.45	22.55	190.84
Other Operating Expenses	-	-	23.04	-	-
Total Operating Expenses	94.27	51.43	72.65	51.53	332.43
Operating Income	-94.27	-51.43	-72.02	-53.08	-325.89
Interest Income	7.61	6.45	-2.11	-59.75	-54.52
Other Non-Operating Income (Expense)	-1.68	-4.72	-8.09	-28.27	13.08
Total Non-Operating Income (Expense)	5.93	1.73	-10.2	-88.02	-41.44
Pretax Income	-88.34	-49.7	-82.22	-141.1	-367.33
Provision for Income Taxes	-	-	-	-0.1	0.5
Net Income	-88.34	-49.7	-82.22	-141.2	-367.82
Minority Interest in Earnings	-42.07	-	-	-	-
Earnings From Discontinued Operations	-	27.47	-125.51	-229.85	-
Net Income to Common	-46.27	-22.23	-207.73	-371.05	-366.83
Shares Outstanding (Basic)	96	81	83	83	76
Shares Outstanding (Diluted)	96	81	83	83	76
Shares Change (YoY)	17.96%	-2.45%	0.86%	8.63%	11.11%
EPS (Basic)	-0.48	-0.28	-2.51	-4.51	-4.83
EPS (Diluted)	-0.48	-0.28	-2.51	-4.51	-4.83
Free Cash Flow	-20.6	-52.72	-72.86	-51.67	-157.81
Free Cash Flow Per Share	-0.22	-0.65	-0.88	-0.63	-2.08
Gross Margin	-	-	100.00%	100.00%	-235.26%
Operating Margin	-	-	-11395.10%	3422.18%	-2353.06%
Profit Margin	-	-	-13009.00%	9104.00%	-2655.86%
FCF Margin	-	-	-11528.60%	3331.59%	-1139.46%
EBITDA	-94.2	-51.17	-71.54	-52.87	-323.6
EBITDA Margin	-	-	-11319.90%	3408.90%	-2336.53%
EBIT	-94.27	-51.43	-72.02	-53.08	-325.89
EBIT Margin	-	-	-11395.10%	3422.18%	-2353.06%
Effective Tax Rate	0.00%	0.00%	0.00%	0.07%	-0.14%

SEC Filings: 10-K · 10-Q